ICYMI, some of this week’s featured content includes AI in dermatology, mental health and PsA treatment, AD therapies, at-home keratosis pilaris treatments, plus more.
This week’s edition of The Mainstream Patient features stories about perioral dermatitis, rosacea, forever chemicals in cosmetics, plus more.
Explore what dermatologic drugs the FDA will decide to approve during July 2021.
Arcutis Biotherapeutics announced early termination of its phase 2a trial evaluating ARQ-252 as a potential treatment for vitiligo citing to inadequate local drug delivery to the skin.
Patients with anxiety/depression and psoriatic arthritis (PsA) are much less likely to achieve long-term remission. Mental health comorbidities need to be a more important part of PsA treatment.
The American Society for Dermatologic Surgery is having two meeting experiences this year, an in-person meeting October 14-17 in Chicago, Illinois and a virtual meeting November 19-21.
From oat oil to acupuncture to prebiotics, there are many topical, oral, and manual options.
OncoSec Medical Inc. and Merck have entered into a supply and clinical trial agreement for pembrolizumab (Keytruda) and tavokinogene telseplasmid (Tavo) for the potential treatment of late-stage metastatic melanoma.
The FDA has expanded the label for pembrolizumab for use as a monotherapy in the treatment of patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation.
The AAD has provided various at-home treatments for keratosis pilaris that physicians can recommend to their patients.
Brickell BioTech, Inc announced the completion of its Cardigan I study and final enrollment of the Cardigan II study.
The introduction of artificial intelligence into dermatology has been met with mixed emotions from the medical community. In this episode, Ade Adamson, MD, MPP, explains the benefits and detriments of the application, accuracy, and potential racial diagnostic bias.
Journey Medical Corporation and Dr. Reddy’s Laboratories Ltd. have joined forces for the development and commercialization of DFD-19 as a treatment for rosacea.